Kai-Wei Chang

Title: Innovations by Inventor Kai-Wei Chang

Introduction

Kai-Wei Chang is a notable inventor based in Newark, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of matrix metalloproteinase (MMP) inhibitors. His work focuses on innovative compounds that have the potential to treat various diseases.

Latest Patents

Kai-Wei Chang holds 2 patents related to matrix metalloproteinase (MMP) inhibitors. His latest patents describe hydantoin-based compounds that are useful as inhibitors of matrix metalloproteinases, specifically targeting macrophage elastase (MMP-12). These patents detail the compositions and methods for using these compounds to inhibit MMP-12 and treat diseases mediated by this enzyme. The diseases include asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Career Highlights

Kai-Wei Chang is currently associated with Foresee Pharmaceuticals USA, Inc. His work at the company emphasizes the development of innovative therapeutic solutions that address critical health issues. His research has the potential to impact the treatment landscape for several serious medical conditions.

Collaborations

Some of his notable coworkers include Wenjin Yang and Suying Liu. Their collaborative efforts contribute to the advancement of research and development in the pharmaceutical field.

Conclusion

Kai-Wei Chang's innovative work in the development of MMP inhibitors showcases his commitment to addressing significant health challenges. His contributions are paving the way for new treatment options for various diseases.